Search Results

Four-Year Data from DESSOLVE Trials Presented for Micell's MiStent

October 13, 2015—Micell Technologies, Inc. announced that 4-year clinical results from the DESSOLVE I and DESSOLVE II trials of the company’s MiStent sirolimus-eluting absorbable polymer coronary stent system (MiStent SES) were presented by Alexandra Lansky, MD, at TCT 2015, the 27th annual Transcatheter Cardiovascular Therapeutics scientific symposium being held October 11–15 in San Francisco, California.

Propensity Analysis Compares the MiStent SES and Xience V at 1 and 3 Years

May 19, 2015—Micell Technologies, Inc. announced the presentation of data from a retrospective cross-study propensity analysis comparing the company’s absorbable polymer coronary MiStent sirolimus-eluting stent (SES) system to Abbott Vascular’s durable polymer coronary Xience V everolimus-eluting stent system.

Sex-Specific Considerations in Myocardial Revascularization Addressed in SCAI Expert Consensus Statement

February 4, 2022—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the publication of an expert consensus statement on sex-specific considerations in myocardial revascularization.

PIONEER III Findings Presented for Sinomed’s Supreme HT DES

November 17, 2020—Sino Medical Sciences Technology Inc. (Sinomed), a Tianjin, China–based developer of neuro- and cardiovascular technologies, announced data from the randomized, global PIONEER III study evaluating the safety and efficacy of the Supreme HT healing-targeted drug-eluting stent (DES).

Shockwave Initiates All-Female EMPOWER CAD Coronary IVL Study

September 19, 2022—Shockwave Medical, Inc. announced that the company has initiated EMPOWER CAD, a coronary artery disease (CAD) intervention study consisting of all female patients to determine whether the positive results from earlier coronary studies of intravascular lithotripsy (IVL) with the Shockwave C2 coronary IVL catheter (which showed similar safety outcomes across both sexes) can be replicated in an expanded, real-world population of female patients with severely calcified coronary lesions.

Study Shows Unprotected TAVR Procedures Produce New Brain Lesions in Nearly All Cases

October 19, 2015—Keystone Heart Ltd. recently announced that findings from the company-sponsored multicenter Neuro-TAVR study were presented at TCT 2015, the 27th annual Transcatheter Cardiovascular Therapeutics scientific symposium, held October 11–15 in San Francisco, California.

Abiomed’s Impella Heart Pump Compared to IABP in High-Risk PCI Study

October 13, 2022—Abiomed announced the publication of an analysis of > 2,000 patients from a large real-world database in the United States comparing outcomes in patients who underwent nonemergent high-risk percutaneous coronary intervention (PCI) with the company’s Impella heart pump (n = 1,447) versus matched patients treated with an intra-aortic balloon pump (IABP; n = 709).

SCAI Announces Recipients of Inaugural JSCAI Editorial Fellowship

February 7, 2023—The Society for Cardiovascular Angiography & Interventions (SCAI) announced the inaugural participants of the JSCAI Editorial Fellowship Program.

Shockwave EMPOWER CAD Evaluates IVL-First Strategy in Female Patients

May 20, 2025—Shockwave Medical, Inc., part of Johnson & Johnson MedTech, announced the 30-day primary endpoint results of the EMPOWER CAD study.

Shockwave Launches C²⁺ IVL Catheter Internationally, Commences All-Female EMPOWER CAD Study

May 15, 2023—Shockwave Medical, Inc. announced the full commercial availability in select international markets of the Shockwave C2+ coronary intravascular lithotripsy (IVL) catheter.

Enrollment Completed in DESSOLVE III Trial of the MiStent SES

December 9, 2015—Stentys announced the completion of patient enrollment in DESSOLVE III randomized clinical trial evaluating the company’s MiStent SES, a sirolimus-eluting absorbable polymer coronary stent system, compared to Abbott Vascular’s Xience everolimus-eluting stent.

Disrupt CAD Demonstrates Consistent Shockwave Coronary IVL Outcomes at 1 Year, Across Calcium Morphologies, and Between Men and Women

November 5, 2021—Data from Shockwave Medical’s Disrupt CAD clinical program demonstrating the safety and effectiveness of Shockwave coronary intravascular lithotripsy (IVL) at 1 year and consistently similar outcomes across calcium morphologies and between men and women were presented in several sessions of TCT 2021 in Orlando, Florida.

DEFLECT III Results Support TriGuard HDH Embolic Deflection Device

August 17, 2015—Alexandra J. Lansky, MD, et al published results from the DEFLECT III trial of the TriGuard HDH embolic deflection device (Keystone Heart, Ltd.) in the European Heart Journal (2015;36:2070–2078). DEFLECT III was conducted to evaluate the safety, efficacy, and performance of the TriGuard device compared with no cerebral protection in patients undergoing transcatheter aortic valve replacement (TAVR). 

Pooled Analysis Supports Keystone Heart's TriGuard Cerebral Protection Device in TAVR Procedures

May 23, 2016—Keystone Heart, Ltd. announced the presentation of a pooled analysis of three prospective and comparable clinical studies of patients undergoing transcatheter aortic valve replacement (TAVR) in the United States and Europe.

Sinomed’s HT Supreme DES Demonstrates Noninferiority to Best-in-Class Devices in Published PIONEER III Trial

October 27, 2021—Sinomed, a Tianjin, China–based developer of neuro- and cardiovascular technologies, announced the publication of results from the PIONEER III clinical trial of the company’s HT Supreme drug-eluting stent (DES) system.

NeuroARC Proposes Classification System for Neurologic Outcomes After Cardiac Procedures

February 6, 2017—The Neurologic Academic Research Consortium (NeuroARC) announced the publication of a consensus paper offering a new classification of neurologic outcomes and testing to better ensure the safety of cardiac procedures.

Safety and Efficacy Data Presented for Keystone Heart's TriGuard Cerebral Protection Device in TAVR Procedures

September 19, 2016—Keystone Heart Ltd. announced the presentation of preliminary safety and efficacy data from real-world experience in 51 patients with the company's TriGuard cerebral embolic protection device when used during transcatheter aortic valve replacement (TAVR).

Emboline Begins IDE Study of Full-Body Embolic Protection Catheter for TAVR

May 9, 2023—Emboline, Inc. announced the first patient has been treated in the “Protect the Head-to-Head Study” (ProtectH2H) of the Emboliner full-body embolic protection catheter.